AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) – AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.

Source: Reuters Medical News